We are monitoring the impact of COVID-19 on Latin America Melanoma Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 796
Share on
Share on

Latin America Melanoma Therapeutics Market Research Report - Segmented By Cancer Stage, Cancer Type, Diagnosis, Treatment & Country (Mexico, Brazil, Argentina, Chile & Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends & Forecast (2021 to 2026)

Pulished: April, 2021
ID: 796
Pages: 145

Latin America Melanoma Therapeutics Market Size (2021 to 2026)

The size of the Melanoma Therapeutics Market in Latin America is estimated to be growing at a CAGR of 13.80% during the forecast period. As a result, the market size is predicted to value USD 0.59 billion by 2026 from USD 0.31 billion in 2021.  The melanoma market in Latin America has seen an unmatched boost in market size due to the dynamically developing nature of melanoma treatments over the recent past.

The market for melanoma therapeutics market in Latin America is growing significantly due to the increasing prevalence of melanoma and improving healthcare facilities. In addition, government initiatives and technical advancements are driving the growth of the market. The extensive ongoing medical research for cancer treatment, drugs, and treatments with various supportive initiatives from government and private organizations are some of the key ideas that can lead to effective treatment options.

According to the WHO, around 132,500 cases of skin cancer occur each year. In addition, a 10% decrease in ozone levels is expected to lead to an increase of 4,600 skin cancer cases worldwide. This is expected to drive demand for melanoma therapeutics during the forecast period. Due to the expiration of the biologics patent in the coming years, many new players are expected to enter the market in this region. Existing companies are undertaking various strategic initiatives to improve their revenue share by introducing better diagnostics devices to gain market growth in Latin America. In addition, the massive increase in the establishment of specialized clinics for the treatment and therapy of skin cancer and the growing awareness of the availability of the treatment is helping to drive the expansion of the market.

Increased investments in R&D activities and technological advancements, which help develop several innovative products for skin cancer treatment, provide key opportunities that can drive market expansion in the years to come.

The high cost of treatment and drug therapy for metastatic melanoma, lack of long-term solutions, and limited availability of drug treatments are the major limiting factors that may hamper the development of the market during the forecast period. In addition, the growth of the market is expected to be hampered between 2020 and 2021 due to the negative impact of the COVID-19 pandemic owing to prioritizing COVID-19 associated symptoms, need for social distancing, and travel ban that affects the import and exports of drugs and diagnostics kits.

This research report on the Latin American Melanoma Therapeutics Market is segmented and sub-segmented into the following categories:

By Cancer Stage:

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

By Cancer Type:

  • Nodular Melanoma
  • Acral Lentiginous Melanoma
  • Superficial Spreading Melanoma
  • Lentigno Maligna Melanoma
  • Amelanotic Melanoma
  • Others

By Diagnosis:

  • Ultrasound
  • Blood Tests
  • Dermatoscopy
  • Sentinel Lymph Node Biopsy
  • X-rays
  • CT Scan

By Treatment:

  • Early Melanoma
  • Advanced Melanoma-Biological Therapy
  • Targeted Therapy
  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Immune Therapy

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, Mexico accounts for the major part of the Latin American Melanoma Therapeutics market, followed by Brazil. This market is projected to grow substantially during the forecast period due to the rising prevalence of melanoma in this region.

The Brazil market for melanoma therapeutics is growing significantly due to the increasing prevalence of melanoma and improving healthcare facilities. Furthermore, the Brazilian government has also developed favorable reimbursement policies for the treatment of melanoma that attempt to meet the unmet needs of patients. This should provide a healthy platform for the growth of the Latin American market. In addition, the presence of many new companies is expected to stimulate the overall market.

Other Latin American regions also have good scope for market growth with an increased awareness of skin disorders and cancer. In addition, in regions such as Mexico, Peru, and Columbia, initiatives are taking place to treat cancer to address unmet patient needs. This should provide a healthy platform for the growth of the Latin American market.

There are also several products in clinical trials across Latin America which are expected to be approved. Hence, the market is expected to continue to experience strong growth during the forecast period.

KEY MARKET PARTICIPANTS:

A few of the prominent companies leading in the Latin America Melanoma Therapeutics Market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By cancer stage                      

                             5.1.1 Stage 0     

                             5.1.2 Stage I      

                             5.1.3 Stage II     

                             5.1.4 Stage III   

                             5.1.5 Stage IV   

              5.2 By cancer type                        

                             5.2.1 Nodular melanoma           

                             5.2.2 Acral lentiginous melanoma          

                             5.2.3 Superficial spreading melanoma  

                             5.2.4 Lentigno maligna melanoma         

                             5.2.5 Amelanotic melanoma     

                             5.2.6 Others     

              5.3 By Diagnosis                           

                             5.3.1 Ultrasound            

                             5.3.2 Blood Tests           

                             5.3.3 Dermatoscopy      

                             5.3.4 Sentinel lymph node biopsy           

                             5.3.5 X-rays       

                             5.3.6 CT Scan    

              5.4 By Treatment                         

                             5.4.1 Early melanoma   

                             5.4.2 Advanced melanoma        

                                           5.4.2.1 Biological therapy

                                           5.4.2.2 Targeted therapy

                                           5.4.2.3 Surgery

                                           5.4.2.4 Chemotherapy

                                           5.4.2.5 Radiotherapy

                                           5.4.2.6 Immune therapy

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 Brazil                          

              6.3 Argentina                  

              6.4 Mexico                      

              6.5 Rest of Latin America                          

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                            8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Bristol-Myers Squibb Co                     

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Merck and Co                         

              9.3 F. Hoffmann-La Roche                        

              9.4 Amgen Inc                

              9.5 Celgene Corp                          

              9.6 Daiichi Sankyo                        

              9.7 Pfizer Inc                   

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures              

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Latin America Melanoma Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  2. Latin America Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  3. Latin America Stage 0 Market, By Region, From 2021 to 2026 (USD Billion)
  4. Latin America Stage I Market, By Region, From 2021 to 2026 (USD Billion)
  5. Latin America Stage II Market, By Region, From 2021 to 2026 (USD Billion)
  6. Latin America Stage III Market, By Region, From 2021 to 2026 (USD Billion)
  7. Latin America Stage IV Market, By Region, From 2021 to 2026 (USD Billion)
  8. Latin America Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  9. Latin America Nodular melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  10. Latin America Acral lentiginous melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  11. Latin America Superficial spreading melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  12. Latin America Lentigno maligna melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  13. Latin America Amelanotic melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  14. Latin America Other cancers Market, By Region, From 2021 to 2026 (USD Billion)
  15. Latin America Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  16. Latin America Ultrasound Market, By Region, From 2021 to 2026 (USD Billion)
  17. Latin America Blood Tests Market, By Region, From 2021 to 2026 (USD Billion)
  18. Latin America Dermatoscopy Market, By Region, From 2021 to 2026 (USD Billion)
  19. Latin America Sentinel lymph node biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  20. Latin America X-rays Market, By Region, From 2021 to 2026 (USD Billion)
  21. Latin America CT Scan Market, By Region, From 2021 to 2026 (USD Billion)
  22. Latin America Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  23. Latin America early melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  24. Latin America advanced melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  25. Latin America Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  26. Latin America Biological therapy Market, By Region, From 2021 to 2026 (USD Billion)
  27. Latin America Targeted therapy Market, By Region, From 2021 to 2026 (USD Billion)
  28. Latin America Surgery Market, By Region, From 2021 to 2026 (USD Billion)
  29. Latin America Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  30. Latin America Radiotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  31. Latin America Immune therapy Market, By Region, From 2021 to 2026 (USD Billion)
  32. Brazil Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  33. Brazil Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  34. Brazil Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  35. Brazil Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  36. Brazil Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  37. Argentina Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  38. Argentina Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  39. Argentina Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  40. Argentina Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  41. Argentina Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  42. Mexico Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  43. Mexico Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  44. Mexico Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  45. Mexico Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  46. Mexico Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample